Amgen Announces New LUMAKRAS Combination Data From Phase 1b

Amgen today announced new combination study results from the Phase 1b CodeBreaK 101 study, a comprehensive global master protocol trial evaluating the safety and efficacy of LUMAKRAS™ the first and only approved KRAS G12C inhibitor, in more than 10 different investigational combination regimens for the treatment of patients with KRAS G12C-mutated cancers. Results from two arms of the study — LUMAKRAS with ...

Related Keywords

United Arab Emirates , Australia , Taiwan , Japan , Hong Kong , Brazil , Colombia , Canada , Umeki , Ankara , Turkey , Mexico , Puerto Rico , Thailand , Israel , Singapore , South Korea , Switzerland , Megan Fox , Trish Rowland , Davidm Reese , Kyowa Kirin Co Ltd , Amgen , Drug Administration , Beigene Ltd , Virtual International Conference On Molecular , Exchange Commission , Therapeutics Inc , European Union , Drugging Difficult Target , International Conference , Molecular Targets , Cancer Therapeutics , Great Britain , Real Time Oncology Review , Marketing Authorization Applications , Important Safety Information , Lung Disease , Prescribing Information , Amgen Oncology , Five Prime Therapeutics , Thousand Oaks , Englj Med ,